We are live on !
Find out more
Great Point Partners Portfolio holdings
AUM
$529M
Turnover
44.44%
1-Year Est. Return
337.4%
This Fund
S&P 500
This Quarter Est. Return
+27.32%
1 Year Est. Return
+337.4%
3 Year Est. Return
+710.06%
5 Year Est. Return
+1,177.67%
10 Year Est. Return
+20,064.23%
AUM
$529M
AUM Growth
+$94M
(+22%)
Cap. Flow
-$41.6M
Cap. Flow % of AUM
Cap. Flow %
-7.87%
Top 10 Holdings %
Top 10 Hldgs %
51.64%
Holding
54
New
12
Increased
7
Reduced
10
Closed
12
Avg Time Held
Equity + Options
0.4
years
Top 10 Avg Time Held
Equity + Options
0.2
years
Top 20 Avg Time Held
Equity + Options
0.4
years
Avg Time Held Equity only
0.5
years
Top 10 Avg Time Held Equity only
0.2
years
Top 20 Avg Time Held Equity only
0.5
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Abivax
ABVX
|
+$23.1M |
| 2 |
Vera Therapeutics
VERA
|
+$15M |
| 3 |
Sagimet Biosciences
SGMT
|
+$13.8M |
| 4 |
Definium Therapeutics
DFTX
|
+$10.5M |
| 5 |
Immix Biopharma
IMMX
|
+$8.61M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apogee Therapeutics
APGE
|
+$31.5M |
| 2 |
Amylyx Pharmaceuticals
AMLX
|
+$16.2M |
| 3 |
KalVista Pharmaceuticals
KALV
|
+$13.6M |
| 4 |
Immunovant
IMVT
|
+$13.6M |
| 5 |
Jade Biosciences
JBIO
|
+$13.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 78.18% |
| 2 | Miscellaneous | 19.78% |
| 3 | Financials | 2.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
26
Relmada Therapeutics
RLMD
$446M
| $5.83M | 1.1% |
842,106
| – | – |
2026 Q1
1 quarter
|
|
27
JATT II Acquisition Corp
JATT
| $5.68M | 1.07% |
+500,000
| New | +$5.31M |
2026 Q2
0 quarters
|
|
28
Cullinan Oncology
CGEM
$781M
| $5.46M | 1.03% |
300,000
| – | – |
2025 Q4
2 quarters
|
|
29
Altimmune
ALT
$412M
| $5.29M | 1% |
+1,741,232
| New | +$5.2M |
2026 Q2
0 quarters
|
|
30
Amanat Acquisition Corp
AMAN
$97.9M
| $5.08M | 0.96% |
+500,000
| New | +$5.05M |
2026 Q2
0 quarters
|
|
31
Rezolute
RZLT
$399M
| $4.95M | 0.94% |
951,809
| – | – |
2024 Q4
6 quarters
|
|
32
Silence Therapeutics
SLN
$1.23B
| $4.94M | 0.93% |
450,000
-570,489
| -56% | -$4.01M |
2025 Q4
2 quarters
|
|
33
Palisade Bio
PALI
$213M
| $4.78M | 0.9% |
2,284,819
-1,120,938
| -33% | -$2.21M |
2026 Q1
1 quarter
|
|
34
Evommune Inc
EVMN
$276M
| $4.32M | 0.82% |
325,000
| – | – |
2025 Q4
2 quarters
|
|
35
SCYNEXIS
SCYX
$35.2M
| $3.84M | 0.73% |
944,292
-1
| -0% | -$6 |
2026 Q1
1 quarter
|
|
36
CALL
Galectin Therapeutics
GALT
$342M
| $3.71M | 0.7% |
800,000
| – | – |
2026 Q1
1 quarter
|
|
37
Enliven Therapeutics
ELVN
$3.77B
| $3.55M | 0.67% |
+70,000
| New | +$2.97M |
2026 Q2
0 quarters
|
|
38
Humacyte
HUMA
$132M
| $2.93M | 0.55% |
3,750,000
| – | – |
2026 Q1
1 quarter
|
|
39
Rein Therapeutics
RNTX
$54.5M
| $2.68M | 0.51% |
+2,575,000
| New | +$3.12M |
2026 Q2
0 quarters
|
|
40
DBV Technologies S.A. American Depositary Shares
DBVT
$702M
| $2.57M | 0.49% |
+156,906
| New | +$2.96M |
2026 Q2
0 quarters
|
|
41
CALL
Anavex Life Sciences
AVXL
$116M
| $1.35M | 0.26% |
521,300
| – | – |
2026 Q1
1 quarter
|
|
42
ProMIS Neurosciences
PMN
$36.8M
| $1.13M | 0.21% |
86,150
-285,252
| -77% | -$3.1M |
2026 Q1
1 quarter
|
|
43
Alkermes
ALKS
$7.88B
| – | – |
-50,000
| Closed | -$1.77M | – |
|
|
44
DELISTED
Apogee Therapeutics
APGE
| – | – |
-374,000
| Closed | -$31.5M | – |
|
|
45
Jade Biosciences
JBIO
$1.02B
| – | – |
-964,462
| Closed | -$13.6M | – |
|
46
Avalo Therapeutics
AVTX
$424M
| – | – |
-124,666
| Closed | -$1.86M | – |
|
47
Compass Therapeutics
CMPX
$148M
| – | – |
-1,350,000
| Closed | -$7.14M | – |
|
48
Context Therapeutics
CNTX
$18.3M
| – | – |
-2,238,496
| Closed | -$5.86M | – |
|
|
49
Immunovant
IMVT
$7.01B
| – | – |
-545,625
| Closed | -$13.6M | – |
|
|
50
DELISTED
KalVista Pharmaceuticals
KALV
| – | – |
-675,000
| Closed | -$13.6M | – |
|
Similar funds
GECH
H2CM
Great Point Partners's Q2 2026 Portfolio in Review
As of Q2 2026, Great Point Partners held 54 positions worth $529M, up 22% from $435M the previous quarter. Its ten largest holdings account for 52% of the portfolio.
Great Point Partners withdrew a net $41.6M in Q2 2026, closing 12 positions and reducing 10 holdings. Its most notable exit was Apogee Therapeutics, an estimated $31.5M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 78% of assets, down from 94% a quarter earlier, followed by Miscellaneous and Financials.
Against the trend, Great Point Partners opened a new position in Abivax worth $27.2M.
- Great Point Partners's largest Q2 2026 buy was Abivax: 204,314 shares worth $27.2M.
- Great Point Partners added most to Vera Therapeutics in Q2 2026, an estimated $15M increase.
- Great Point Partners's biggest Q2 2026 reduction was Amylyx Pharmaceuticals, cutting an estimated $16.2M.
- Great Point Partners fully exited Apogee Therapeutics in Q2 2026, selling an estimated $31.5M.
- Great Point Partners's ten largest holdings make up 52% of its $529M portfolio in Q2 2026.
- Great Point Partners opened 12 new positions and closed 12 in Q2 2026.
- Great Point Partners's portfolio value rose 22% quarter-over-quarter to $529M.
Based on Great Point Partners's 13F filing for Q2 2026, filed 14 Aug 2026.